Allenex jan-sep: 85,3 msek (71,2) net sales

Allenex interim report JANUARY – SEPTEMBER 2012
For the third quarter July - September

  · Net sales for the quarter amounted to SEK 26.7 million (26.3), corresponding
to a 1.5 percent increase compared to the same period last year. Sales were
impacted by a negative currency effect of SEK 1.4 million compared to the year
before, and the growth rate adjusted for currency effects is 6.8 percent.
  · Operating income (EBIT) for the quarter was SEK 1.3 million (-0.2), with
currency effects having a negative impact of SEK 2.6 million on results.
  · Operating margin for the quarter was 4 percent (-1).
  · Loss after tax for the quarter was SEK 1.8 million (-59.3).
  · Loss per share for the quarter, basic and diluted, was SEK 0.01 (-0.96).

For the January – September period

  · Net sales for the period amounted to SEK 85.3 million (71.2), corresponding
to an increase of 20 percent compared to the same period last year (Olerup GmbH
became a part of the group on June 1, 2011). Sales were impacted by a negative
currency effect of SEK 1.1 million compared to last year.
  · Operating income (EBIT) for the period was SEK 7.4 million (-12.1). The
results were impacted by a negative currency effect of SEK 2.3 million.
  · Operating margin for the period was 8 percent (-16).
  · Loss after tax for the period was SEK 0.6 million (-432.9).
  · Earnings per share for the period, basic and diluted, were SEK 0.00 (-6.96).
  · Equity per share was SEK 1.79 (9.19) and the equity/assets ratio was 60
percent (36) percent at the period end.

Significant events in the third quarter

  · Allenex, in collaboration with its local distributor in France, won a public
tender offered by the French blood center organization (EFS). The estimated
value of the tender for Allenex is SEK 6 million per year over a four year
period (a total of SEK 24 million). As half of the laboratories covered by the
tender are already clients today, the contract will entail a net effect or
direct sales increase of around SEK 3 million per year (a total of SEK 12
million).

CEO Anders Karlsson’s comments on the third quarter 2012:
“Allenex continues to streamline its operations towards transplantation
diagnostics. In the third quarter, we received good news that we had won a
public tender bid in France with our SSP typing products. This is solid proof of
the high quality and cost-effectiveness of our products. During the quarter, we
also received our first orders for Conexio SBT. This introduction has gone
slower than anticipated, but we now expect more as well as larger centers to
follow suit. We also achieved further cost reductions in the third quarter, with
lower costs internally and externally.”


For more information please contact:
Anders Karlsson, CEO Allenex AB, ph: +4670-918 00 10, e-mail:
anders.karlsson@allenex.se
Yvonne Axelsson, CFO Allenex AB ph: +468-508 939 72, e-mail
yvonne.axelsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities
Markets Act And/or the Financial Instruments Trading Act. The information was
submitted for publication on November 20, 2012, at 16.00 CET. Allenex is a life
science-company that develops, manufacture, market and sell products for safer
transplants of organs and bone marrow on the global market. Allenex is listed on
NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 52 persons are employed in the
Allenex group.